☆ 4.7 Article

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Radiology, Nuclear Medicine & Medical Imaging

[68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment

Steffie M. B. Peters et al.

Summary: Predicting absorbed doses based on [Ga-68]Ga-PSMA-PET/CT scans can improve patient selection and individualize treatment in [Lu-177]Lu-PSMA therapy. Results show that PET scans can be used to predict absorbed doses to organs and lesions, aiding in treatment management and potentially increasing therapy personalization.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

177Lu-PSMA-617 versus docetaxel in chemotherapy-naive metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial

Swayamjeet Satapathy et al.

Summary: Lu-177-PSMA-617 has been shown to be safe and non-inferior to docetaxel in the treatment of mCRPC, suggesting it could be potentially used earlier in the disease course rather than solely reserved for advanced end-stage disease.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

添加到收藏夹

Meeting Abstract Oncology

Dosimetry of 177Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: results from the VISION trial sub-study.

Ken Herrmann et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

Predicting the outcome of mCPRC patients after Lu-177 PSMA therapy using semi-quantitative and visual criteria in baseline PSMA PET: An international multicenter retrospective study.

Masatoshi Hotta et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry

Christiane Schuchardt et al.

Summary: The objective of this study was to assess the safety, kinetics, and dosimetry of Lu-177-labeled PSMA small molecules (Lu-177-PSMA I&T and Lu-177-PSMA-617) in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing PSMA radioligand therapy (PRLT). The study showed that both Lu-177-PSMA I&T and Lu-177-PSMA-617 demonstrated favorable safety and comparable absorbed tumor doses. However, there was variability in dosimetry parameters between patients, suggesting the need for personalized dosimetry in PRLT.

JOURNAL OF NUCLEAR MEDICINE (2022)

添加到收藏夹

Editorial Material Radiology, Nuclear Medicine & Medical Imaging

Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial

Phillip H. Kuo et al.

JOURNAL OF NUCLEAR MEDICINE (2022)

添加到收藏夹

Review Radiology, Nuclear Medicine & Medical Imaging

Dosimetry in Lu-177-PSMA-617 prostate-specific membrane antigen targeted radioligand therapy: a systematic review

Amit Nautiyal et al.

Summary: This study conducted a systematic review on the absorbed dose received by organs at risk and tumor lesions in Lu-177-PSMA therapy. The results showed that lacrimal glands and salivary glands were the major critical organs, and tumor lesions received 3-6 times higher absorbed doses compared to organs at risk.

NUCLEAR MEDICINE COMMUNICATIONS (2022)

添加到收藏夹

Article Oncology

Early PSA Change after [177Lu]PSMA-617 Radioligand Therapy as a Predicator of Biochemical Response and Overall Survival

Felix Kind et al.

Summary: This study aimed to assess the prognostic value of early PSA measurements during PSMA-RLT. The results showed that PSA changes as early as four weeks after PSMA-RLT can predict long-term biochemical and PET-based imaging response, as well as overall survival.

CANCERS (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study)

Fadi Khreish et al.

Summary: Preliminary data and recent large trials suggest that Lu-177-PSMA-617 RLT targeting PSMA is safe and effective in treating mCRPC. A real-world study of 254 men with late-stage mCRPC showed the therapy was well-tolerated and associated with better overall survival when early biochemical disease control was achieved. Further prospective studies earlier in the disease course may be warranted.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome

Steffie M. B. Peters et al.

Summary: This study found that the kinetics of [Lu-177]Lu-PSMA therapy in mHSPC patients are similar to those in mCRPC patients, indicating less concern for tumor sink effect. The absorbed dose in lesions was high and correlated with treatment response.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands

Katarina Sjogreen Gleisner et al.

Summary: The EANM Dosimetry Committee aims to provide recommendations and guidance on patient-specific dosimetry for scientists and clinicians. This paper provides an overview of reported dosimetry data for therapies using 177Lu-labelled radiopharmaceuticals, and summarizes the current understanding of radiation-induced side effects on normal tissues and dose-effect relationships for tumors. Dosimetry methods and data for various organs and tissues, as well as guidance based on current evidence, are presented.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Kidney Doses in 177Lu-Based Radioligand Therapy in Prostate Cancer: Is Dose Estimation Based on Reduced Dosimetry Measurements Feasible?

Michael Mix et al.

Summary: This study analyzed the monitoring and estimation methods of kidney dose in prostate cancer patients undergoing radioligand therapy. The results showed that pretherapeutic kidney function is not a reliable predictor of subsequent kidney dose, and individual first-cycle dose estimation is more accurate. The integration of dose information from multiple cycles further improves the prediction.

JOURNAL OF NUCLEAR MEDICINE (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Pretherapeutic Comparative Dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer

Benedikt Feuerecker et al.

Summary: A comparison study of two PSMA ligands found that Lu-177-rhPSMA-7.3 had 2-3 times higher tumor absorbed doses than Lu-177-PSMA I&T, with higher absorbed doses in normal organs as well. Overall, both radiopharmaceuticals showed similar average therapeutic indices with considerable interpatient variability, indicating the potential for Lu-177-rhPSMA-7.3 to achieve therapeutic efficacy similar to Lu-177-PSMA I&T with lower injected activity amounts.

JOURNAL OF NUCLEAR MEDICINE (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with 177Lu-PSMA Therapy: A Multicenter Retrospective Analysis

Masatoshi Hotta et al.

Summary: This study assessed the outcomes of patients with metastatic castration-resistant prostate cancer treated with 177Lu-prostate-specific membrane antigen (PSMA) who did not meet the criteria for the VISION trial based on PSMA PET/CT results. The results showed that these patients had worse outcomes compared to those who met the criteria, indicating a need for refinement in patient selection for better treatment outcomes.

JOURNAL OF NUCLEAR MEDICINE (2022)

添加到收藏夹

Review Endocrinology & Metabolism

177Lu-PSMA radioligand therapy effectiveness in metastatic castration-resistant prostate cancer: An updated systematic review and meta-analysis

Mohammad S. Sadaghiani et al.

Summary: PSMA-targeted endoradiotherapy/radioligand therapy (PRLT) is effective in castration resistant prostate cancer (CRPC). The evaluation of PRLT mainly focuses on prostate-specific antigen (PSA) decline and overall survival (OS). The study found that PRLT can lead to a higher proportion of patients with PSA decline and prolong overall survival in CRPC patients.

PROSTATE (2022)

添加到收藏夹

Article Oncology

Assessment of salivary gland function after 177Lu-PSMA radioligand therapy: Current concepts in imaging and management

Sonia Mahajan et al.

Summary: PSMA-617 radioligand therapy has shown potential efficacy in patients with metastatic prostate cancer, but it may cause radiation toxicity to non-target tissues such as salivary glands. The exact mechanism and treatment strategies for radiation-mediated salivary gland toxicity are still unclear, but they are being evaluated and researched.

TRANSLATIONAL ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer-a state of the art review

Isabel Heidegger et al.

Summary: This narrative review article summarizes recent studies investigating predictive and prognostic clinical, imaging-based, and molecular biomarkers to select the most suitable prostate cancer patients for 177Lu-PSMA-617 radioligand therapy.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Examining Absorbed Doses of Indigenously Developed 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy

Kamaldeep et al.

Summary: The study aimed to estimate absorbed doses in mCRPC patients treated with Lu-177-PSMA-617, comparing doses to normal organs and tumor lesions across treatment cycles. Results showed comparable doses to literature, with lacrimal glands receiving highest absorbed dose. Cumulative activity up to 32.5 GBq of Lu-177-PSMA-617 over 4-5 cycles appeared safe and feasible for full therapeutic window.

CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)

Hojjat Ahmadzadehfar et al.

Summary: In this multicenter analysis, mCRPC patients receiving Lu-177-PSMA-617 therapy had a significantly longer OS if they had not received prior chemotherapy.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy

Fadi Khreish et al.

Summary: The study retrospectively analyzed the efficacy of Lu-177-PSMA-617 RLT in treating liver metastases of mCRPC patients, showing that it effectively controlled liver metastases and improved PFShep and OS. The study also found that hepatic tumor burden did not appear to have a significant relationship with treatment efficacy.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy

Mark Konijnenberg et al.

Summary: The EC Directive 2013/59/Euratom requires individual planning of target volume exposures and appropriate involvement of medical physics experts in nuclear medicine treatments. The EANM proposes three levels of compliance to the optimization principle, with standardized treatments falling under ICRU level 1 and non-standardized treatments under ICRU level 2, encouraging research for potential adoption of ICRU level 3 in the future.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Patient-Specific Dosimetry in Radioligand Therapy (RLT) for Metastatic Prostate Cancer Using 177Lu-DKFZ-PSMA-617

Elahe Mahmoudi et al.

Summary: Lu-177-DKFZ-PSMA-617 is a promising treatment for metastatic prostate cancer patients, with individualized dosimetry calculations showing large inter-individual variations in organ dose, highlighting the importance of patient-specific dosimetry and treatment planning.

NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

添加到收藏夹

Editorial Material Radiology, Nuclear Medicine & Medical Imaging

PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy

Jeremie Calais et al.

JOURNAL OF NUCLEAR MEDICINE (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Predictive factors of tumor sink effect: Insights from 177Lu-Prostate-specific membrane antigen therapy

Murat Tuncel et al.

Summary: The study investigated predictive factors of the tumor sink effect in patients receiving Lu-177-PSMA therapy for progressive metastatic castration-resistant prostate cancer (mCRPC). It found that Ga-68-PSMA TLPI, pre-therapy PSA, and PSA velocity were predictors of TSE, which can lead to increased tumoral doses while sparing healthy organs and potentially increasing therapeutic efficacy in clinical trials.

ANNALS OF NUCLEAR MEDICINE (2021)

添加到收藏夹

Article Oncology

Nuclear medicine theranostics comes of age

Ken Herrmann et al.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Michael S. Hofman et al.

Summary: [Lu-177]Lu-PSMA-617 showed a higher PSA response and fewer grade 3-4 adverse events compared to cabazitaxel in men with metastatic castration-resistant prostate cancer.

LANCET (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T

Julia Brosch-Lenz et al.

Summary: This study compared different methods for bone lesion dosimetry in mCRPC patients receiving Lu-177-PSMA therapy, and found that patient-individual Monte Carlo absorbed dose simulation is capable of accounting for heterogeneous densities in bone lesions. Lesion-individual density weighting was shown to be necessary for TSV or VSV methods in Lu-177-PSMA therapy bone lesion dosimetry.

EJNMMI PHYSICS (2021)

添加到收藏夹

Article Medicine, General & Internal

Correlation of an Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after 177Lu-PSMA-617 Radioligand Therapy

Friederike Voelter et al.

Summary: The study found that single index-lesion-based SPECT dosimetry correlates well with the response to PSMA-RLT, suggesting it may be a fast and feasible dosimetry approach for clinical routine.

DIAGNOSTICS (2021)

添加到收藏夹

Article Oncology

Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study

Bastiaan M. Prive et al.

Summary: In this prospective study, Lu-177-PSMA appeared to be a feasible and safe treatment modality for patients with low-volume metastatic hormone-sensitive prostate cancer, showing good treatment effect and minimal adverse events.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Review Urology & Nephrology

A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer

Mohammad S. Sadaghiani et al.

Summary: PRLT treatment shows promising potential in treating CRPC, with a relatively high number of PSA responders and a low rate of severe toxicity.

EUROPEAN UROLOGY (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Lu177-PSMA therapy for men with advanced prostate cancer: 18 months survival analysis in a single Australian tertiary institution

Annaleis Tatkovic et al.

Summary: Radioligand therapies targeting PSMA, like Lutetium-177, have shown promising outcomes in mCRPC patients. Our study found an 18-month overall survival rate of 64% in patients undergoing LuPSMA therapy, with baseline serum PSA, SUVmax, and biochemical response as prognostic markers for increased survival.

JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Assessing Response to 177Lu-PSMA Radioligand Therapy Using Modified PSMA PET Progression Criteria

Kerstin Michalski et al.

Summary: This study assessed the feasibility of PPP criteria in patients undergoing PSMA RLT and found that PPP criteria are reproducible and highly prognostic for OS.

JOURNAL OF NUCLEAR MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients

Madhav Prasad Yadav et al.

Summary: This study focused on the long-term outcomes of mCRPC patients treated with Lu-177-PSMA-617 RLT. Results showed favorable efficacy with potential for prolonged survival, but further research on prognostic factors within the patient cohort is needed.

PLOS ONE (2021)

添加到收藏夹

Article Oncology

In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2nd Cycle Is Better Predictor of Overall Survival of Prostate Cancer Patients Treated With 177Lu-PSMA

Vikas Prasad et al.

Summary: This study evaluated the role of interim PSMA PET/CT after the 2nd cycle of RLT for early prediction of overall survival in mCRPC patients undergoing RLT with Lu-177-PSMA. The results showed that PET/CT response evaluation is predictive of overall survival and progression of the disease, while PSA response has limited predictive value.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy

Florian Rosar et al.

Summary: The study evaluated and compared the feasibility of different approaches of image-based absorbed dose estimation for patient-individual PSMA-targeted radioligand therapy. Hybrid dosimetry showed high accuracy in estimation of absorbed dose compared to 3D dosimetry for normal organs and bone metastases, indicating its feasibility for individualized PSMA-RLT.

EJNMMI PHYSICS (2021)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients

Murali Kesavan et al.

Summary: BPH, a common issue in male population, becomes more prevalent with age. Although not malignant, its symptoms such as frequent urination, nocturia, and difficulty urinating can significantly impact quality of life. Therefore, timely treatment is crucial for improving patient's quality of life.

DIAGNOSTICS (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Patient dosimetry of 177Lu-PSMA I&T in metastatic prostate cancer treatment: the experience in Thailand

Kotchakorn Chatachot et al.

Summary: The study aimed to determine radiation dosimetry for Lu-177-PSMA imaging and therapy in Thai patients with metastatic prostate cancer. Results indicated that the treatment can be administered with higher activities and more cycles without damaging normal organs, based on absorbed dose coefficients calculated for various organs.

ANNALS OF NUCLEAR MEDICINE (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort

Jeremie Calais et al.

Summary: This prospective phase 2 trial aimed to assess the efficacy of Lu-177-PSMA therapy in patients with progressive metastatic castrate-resistant prostate cancer. The results suggest that the efficacy profile of Lu-177-PSMA appeared to be favorable with comparable outcomes between the two activity regimens (6.0 vs. 7.4 GBq).

JOURNAL OF NUCLEAR MEDICINE (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)

Jeremie Calais et al.

Summary: The study indicates that Lu-177-PSMA-617 is safe and well-tolerated at doses of 6.0 and 7.4 GBq per cycle, with side effects easily managed. Further clinical trials with individualized dosimetry and different administration schemes are needed to optimize treatment efficacy.

JOURNAL OF NUCLEAR MEDICINE (2021)

添加到收藏夹

Article Oncology

Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study

Andrei Gafita et al.

Summary: Nomograms developed in this study can predict outcomes after Lu-177-PSMA in patients with mCRPC. These predictive models can assist in guiding clinical trial design and individual clinical decision-making, especially in institutions where Lu-177-PSMA is introduced as a novel therapeutic option.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Oliver Sartor et al.

Summary: The radioligand therapy with Lu-177-PSMA-617 prolonged both imaging-based progression-free survival and overall survival in patients with PSMA-positive metastatic castration-resistant prostate cancer when added to standard care. Adverse events were more common with Lu-177-PSMA-617 but did not significantly impact quality of life.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Combined 177Lu-PSMA-617 PRLT and abiraterone acetate versus 177Lu-PSMA-617 PRLT monotherapy in metastatic castration-resistant prostate cancer: An observational study comparing the response and durability

Sonam Suman et al.

Summary: The combination of Lu-177-PSMA-617 PRLT and AA therapy showed significant improvement in symptomatic response, PFS, and OS compared to Lu-177-PSMA-617 PRLT monotherapy in mCRPC patients in this study.

PROSTATE (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Prognostic importance of prostatic specific antigen response in patients who received Lutetium-177 prostate-specific membrane antigen treatment for castration resistant prostate cancer

Cigdem Soydal et al.

Summary: Serum PSA level during RLT with Lu-177 PSMA remains a clinically significant factor to predict OS times. About twenty percent of patients who were not responder after the first cycle could become responder after the last cycle. Non-responder patients can achieve a response with further treatments.

QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

添加到收藏夹

Article Oncology

Streamlined Schemes for Dosimetry of Lu-177-Labeled PSMA Targeting Radioligands in Therapy of Prostate Cancer

Jens Kurth et al.

Summary: In patients with advanced castration-resistant prostate cancer, PSMA radioligand therapies have shown promising results in terms of clinical safety and efficacy. The study evaluated different dosimetric methodologies and found that a streamlined dosimetric approach based on single time-point imaging at 48 hours post injection in cycles 2 to 6, taking into account kinetic results from a full dosimetric scheme in cycle 1, is feasible and valid. This simplified approach may have a significant impact on dosimetry management during [Lu-177]Lu-PSMA-617 radioligand therapy.

CANCERS (2021)

添加到收藏夹

Article Oncology

Response and Toxicity to the Second Course of 3 Cycles of 177Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer

Sazan Rasul et al.

Summary: The study found that a second course of three cycles of [Lu-177]Lu-PSMA radioligand therapy (PSMA-RLT) every 4 weeks in mCRPC patients was well tolerated and associated with promising response rates and overall survival. The patients who only had lymph node metastases survived longer, while those with bone metastases had a shorter survival. Levels of PSA prior to therapy remained significant for overall survival. Hemoglobin and platelet levels decreased after the third cycle, but severe adverse events were rare.

CANCERS (2021)

添加到收藏夹

Article Oncology

Renal Safety of [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function

Florian Rosar et al.

Summary: In this study, it was found that patients with pre-treatment chronic kidney failure experienced significant improvement in renal function after PSMA-RLT treatment, and there was no significant correlation between the change in glomerular filtration rate and administered activities of [Lu-177]Lu-PSMA-617. Therefore, the nephrotoxic potential of [Lu-177]Lu-PSMA-617 RLT may be overestimated.

CANCERS (2021)

添加到收藏夹

Article Oncology

PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under 177Lu-PSMA-617 Radioligand Therapy

Liam Widjaja et al.

Summary: PSMA expression level in metastases derived from PSMA-targeted molecular imaging prior to RLT can better predict patients' responses to RLT compared to tumor volume. High age and high PSMA expression in patients scheduled for RLT identify patients with early biochemical response, suggesting potential for PET-guided treatment intensification in selected patients.

CANCERS (2021)

添加到收藏夹

Article Urology & Nephrology

Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [177Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer

Judith Stangl-Kremser et al.

Summary: Treatment with [Lu-177]-PSMA-617 shows promise for patients with castration-resistant prostate cancer, but the presence of PSMA at biopsy is not a reliable predictor of treatment response. Further studies are needed to determine which metastatic sites will respond to this therapy.

EUROPEAN UROLOGY OPEN SCIENCE (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer

Sazan Rasul et al.

Summary: Baseline hemoglobin level is an independent predictor for therapy response and survival in patients receiving PSMA-RLT every 4 weeks. Both baseline PSA <= 650 mu g/L and normal Hb levels were associated with longer survival.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

添加到收藏夹

Article Urology & Nephrology

Renal outcomes of radioligand therapy: experience of 177lutetium-prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer

Marat Gallyamov et al.

CLINICAL KIDNEY JOURNAL (2020)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks

Sazan Rasul et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration-resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up

Johanna Maffey-Steffan et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer

John Violet et al.

JOURNAL OF NUCLEAR MEDICINE (2020)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Response Prediction of 177Lu-PSMA-617 Radioligand Therapy Using Prostate-Specific Antigen, Chromogranin A, and Lactate Dehydrogenase

Hendrik Rathke et al.

JOURNAL OF NUCLEAR MEDICINE (2020)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients

Madhav Prasad Yadav et al.

CLINICAL NUCLEAR MEDICINE (2020)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis

Robert Seifert et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Radiation Dosimetry in Lu-177-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors

Price A. Jackson et al.

JOURNAL OF NUCLEAR MEDICINE (2020)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients

Giovanni Paganelli et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)

添加到收藏夹

Article Endocrinology & Metabolism

Influence of short-term dexamethasone on the efficacy of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer

Thorsten Derlin et al.

PROSTATE (2020)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Neuroendocrine Differentiation and Response to PSMA-Targeted Radioligand Therapy in Advanced Metastatic Castration-Resistant Prostate Cancer: A Single-Center Retrospective Study

Thorsten Derlin et al.

JOURNAL OF NUCLEAR MEDICINE (2020)

添加到收藏夹

Article Oncology

Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer

Moran Gadot et al.

CANCERS (2020)

添加到收藏夹

Article Oncology

A Retrospective Analysis of the Safety and Activity of Lutetium-177-PSMA Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer

Raya Leibowitz et al.

ONCOLOGIST (2020)

添加到收藏夹

Article Urology & Nephrology

Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study

Andrei Gafita et al.

EUROPEAN UROLOGY (2020)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry

Andreas Rinscheid et al.

EJNMMI PHYSICS (2020)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Estimation of [177Lu]PSMA-617 tumor uptake based on voxel-wise 3D Monte Carlo tumor dosimetry in patients with metastasized castration resistant prostate cancer

Theresa Ida Goetz et al.

NUKLEARMEDIZIN-NUCLEAR MEDICINE (2020)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Improving quality of life in patients with metastatic prostate cancer following one cycle of(177)Lu-PSMA-617 radioligand therapy: a pilot study

Milka Marinova et al.

NUKLEARMEDIZIN-NUCLEAR MEDICINE (2020)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years

Majid Assadi et al.

WORLD JOURNAL OF NUCLEAR MEDICINE (2020)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Dose Calculations and Dose-Effect Relationships in 177Lu-PSMA I&T Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer

Sandra Barna et al.

CLINICAL NUCLEAR MEDICINE (2020)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Modeling and Predicting Tumor Response in Radioligand Therapy

Peter Kletting et al.

JOURNAL OF NUCLEAR MEDICINE (2019)

添加到收藏夹

Article Oncology

Results of a Prospective Phase 2 Pilot Trial of 177Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression

Louise Emmett et al.

CLINICAL GENITOURINARY CANCER (2019)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT

Hendrik Rathke et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)

添加到收藏夹

Article Oncology

Neuroendocrine differentiation of prostate cancer leads to PSMA suppression

Martin K. Bakht et al.

ENDOCRINE-RELATED CANCER (2019)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer

Alexander Heinzel et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Clinical Outcomes of 177Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy

Thomas W. Barber et al.

JOURNAL OF NUCLEAR MEDICINE (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

Dosimetry of 177Lu-PSMA-617 after Mannitol Infusion and Glutamate Tablet Administration: Preliminary Results of EUDRACT/RSO 2016-002732-32 IRST Protocol

Anna Sarnelli et al.

MOLECULES (2019)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Lu177-PSMA therapy for men with advanced prostate cancer: Initial 18 months experience at a single Australian tertiary institution

Rhiannon McBean et al.

JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY (2019)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

The use of molecular volumetric parameters for the evaluation of Lu-177 PSMA I&T therapy response and survival

Emine Acar et al.

ANNALS OF NUCLEAR MEDICINE (2019)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

First Experience With 177Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands

Ludwike van Kalmthout et al.

CLINICAL NUCLEAR MEDICINE (2019)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Pretherapeutic 68Ga-PSMA-617 PET May Indicate the Dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in Main Organs and Tumor Lesions

Jingnan Wang et al.

CLINICAL NUCLEAR MEDICINE (2019)

添加到收藏夹

Article Urology & Nephrology

Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer

Alec Paschalis et al.

EUROPEAN UROLOGY (2019)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

3D Monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3D localization of active bone marrow via Tc-99m-anti-granulocyte antibody SPECT/CT

Astrid Gosewisch et al.

EJNMMI RESEARCH (2019)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer

Bernhard Grubmueller et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer

Anna Yordanova et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)

添加到收藏夹

Article Urology & Nephrology

Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer

Matthias M. Heck et al.

EUROPEAN UROLOGY (2019)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Therapeutic efficacy, prognostic variables and clinical outcome of 177Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-a-vis Gleason score in such cohort

Sonam Suman et al.

BRITISH JOURNAL OF RADIOLOGY (2019)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes

John Violet et al.

JOURNAL OF NUCLEAR MEDICINE (2019)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Efficacy and safety of 177Lutetium-prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer patients: First experience in West Asia - A prospective study

Ramin Akbarian Aghdam et al.

WORLD JOURNAL OF NUCLEAR MEDICINE (2019)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Safety Profile and Therapeutic Efficacy of One Cycle of Lu177-PSMA in End-Stage Metastatic Castration-Resistant Prostate Cancer Patients with Low Performance Status

Manoj Gupta et al.

NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)

添加到收藏夹

Article Medicine, Research & Experimental

Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving 177Lu-PSMA-617

Katharina Kessel et al.

THERANOSTICS (2019)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Delayed response after repeated Lu-177-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer

Kambiz Rahbar et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival

K. Rahbar et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Repeated 177Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq

Hendrik Rathke et al.

JOURNAL OF NUCLEAR MEDICINE (2018)

添加到收藏夹

Article Oncology

Salvage Radiopeptide Therapy of Advanced Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen: Efficacy and Safety in Routine Practice

Murali Kesavan et al.

CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2018)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma

Ambreen Khawar et al.

CLINICAL NUCLEAR MEDICINE (2018)

添加到收藏夹

Article Oncology

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

Michael S. Hofman et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Review Radiology, Nuclear Medicine & Medical Imaging

SNMMI Procedure Standard/EANM Practice Guideline for Diuretic Renal Scintigraphy in Adults With Suspected Upper Urinary Tract Obstruction 1.0

Andrew T. Taylor et al.

SEMINARS IN NUCLEAR MEDICINE (2018)

添加到收藏夹

Article

Role of textural heterogeneity parameters in patient selection for 177Lu-PSMA therapy via response prediction

Zain Khurshid et al.

Oncotarget (2018)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Patient-specific image-based bone marrow dosimetry in Lu-177-[DOTA0,Tyr3]-Octreotate and Lu-177-DKFZ-PSMA-617 therapy: investigation of a new hybrid image approach

Astrid Gosewisch et al.

EJNMMI RESEARCH (2018)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Relevant tumor sink effect in prostate cancer patients receiving 177Lu-PSMA-617 radioligand therapy

Christian Filss et al.

NUKLEARMEDIZIN-NUCLEAR MEDICINE (2018)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Radiation Dosimetry for 177Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions

Shozo Okamoto et al.

JOURNAL OF NUCLEAR MEDICINE (2017)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients

Kambiz Rahbar et al.

JOURNAL OF NUCLEAR MEDICINE (2017)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617

Justin Ferdinandus et al.

JOURNAL OF NUCLEAR MEDICINE (2017)

添加到收藏夹

Article Oncology

Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer

Wolfgang P. Fendler et al.

ONCOTARGET (2017)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates

Lorenza Scarpa et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer

Axel Braeuer et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617

Hojjat Ahmadzadehfar et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer

Madhav P. Yadav et al.

NUCLEAR MEDICINE COMMUNICATIONS (2017)

添加到收藏夹

Article Oncology

Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy

Hojjat Ahmadzadehfar et al.

ONCOTARGET (2017)

添加到收藏夹

Article Oncology

Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride

Hojjat Ahmadzadehfar et al.

ONCOTARGET (2017)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry

Levent Kabasakal et al.

MOLECULAR IMAGING AND RADIONUCLIDE THERAPY (2017)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Dosimetry for Lu-177-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer

Andreas Delker et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)

添加到收藏夹

Article Oncology

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

Howard I. Scher et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis

Kambiz Rahbar et al.

JOURNAL OF NUCLEAR MEDICINE (2016)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617

Clemens Kratochwil et al.

JOURNAL OF NUCLEAR MEDICINE (2016)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy

Richard P. Baum et al.

JOURNAL OF NUCLEAR MEDICINE (2016)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [177Lu]DKFZ-PSMA-617

Melanie Hohberg et al.

MOLECULAR IMAGING AND BIOLOGY (2016)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer

Levent Kabasakal et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study

Hojjat Ahmadzadehfar et al.

EJNMMI RESEARCH (2015)

添加到收藏夹

Article Oncology

Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer

Scott T. Tagawa et al.

CLINICAL CANCER RESEARCH (2013)

添加到收藏夹

Article Oncology

Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis

Sebastian Mannweiler et al.

PATHOLOGY & ONCOLOGY RESEARCH (2009)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.